The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

In addition to Raymond James, Viking Therapeutics also received a Buy from William Blair’s Andy Hsieh in a report issued yesterday. However, on the same day, Citi maintained a Hold rating on Viking ...

In a report released today, Justin Zelin from BTIG reiterated a Buy rating on Viking Therapeutics, with a price target of $125.00. The company’s shares opened today at $26.00. Take advantage of ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

After Viking Therapeutics (VKTX) yesterday announced 13-week Phase 2 data for VK2735, an oral GIP/GLP-1-based candidate for obesity, Mizuho notes ...

Unusual total active option classes on open include: Stratasys ( SSYS ), Hertz Global Holdings ( HTZ ), Estee Lauder ( EL ), Lowe’s ( LOW ), Annaly Capital ( NLY ), Viking Therapeutics ( VKTX ), Baidu ...